Join UNITY Biotechnology in-person or virtually for its 2024 Investor and Analyst Day, featuring presentations from prominent ophthalmology key opinion leaders and company management.

The event will focus on the ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Safety and efficacy 24-week data is expected in the first quarter of 2025 and 36-week data is expected in the second quarter of 2025.

A live question and answer session will follow the formal presentations.